McG COVID -19 Biobank

McGill Clinical Genomics and COVID19 Biobank
The JGH Site of the Biobanque Québec COVID-19

The McGill Clinical Genomics program (McG) aims to implement hospital-based genomic medicine building on robust research to improve clinical care. McG seeks to improve disease diagnosis and risk-stratification, the efficiency of test ordering and prediction of drug responses that will deliver benefits to person-centered patient care and value to the wider healthcare system and across the CIUSSS du Centre-Ouest-de-l’Île-de-Montréal/Center West Montreal.

McG COVID-19 Biobank

About our Biobank




We are collecting blood samples and information about your health to understand the causes and risk factors for COVID-19 and its complications.                                                        




You are eligible to participate IF:

  • You have or had flu- like symptoms
  • You have undergone, or you will
  • undergo, a COVID-19 nasal swab test              
  • You are a Canadian Citizen, permanent
  • resident , or landed immigrant .



  • We will ask you a few quest ions about your health. The quest ions will take a few minutes.
  • Then, we will coordinate the blood draw for the research study.
  • Later, we may call you for further follow-up.


PDF icon Our Newsletter ENPDF icon Our Newsletter FR


How will the information collected be used?

The McGill Clinical Genomics Biobank will undertake genetic studies and other health research studies. All of this data will be identified by a code and remain confidential. We intend to share this data with qualified researchers in academia and industry, after approval, to support studies that help to improve understanding of risk factors, causes of diseases, prediction of drug responses and improvement of clinical care in COVID-19 infection.


For the latest information on McGill's response to COVID-19, please visit the Coronavirus Information website.


For Researchers

Biobanque Québec COVID-19 Data Release 2

The JGH Site of the Biobanque Québec COVID-19 ( has collected samples and/or data from over 768 individuals. Extensive phenotypic data and Whole-Genome-Sequence data from BQC19 JGH site participants will be released in the second data release for use by approved investigators. This data release process will be managed by The McGill Interdisciplinary Initiative in Infection and Immunity (MI4) and is being released rapidly to enable COVID-19 research.

Applications for access to data are encouraged from investigators at academic institutions, within industry and from all countries.

Interested parties should fill out the Access Form and send to [at] 

PDF icon Description of Biobanque Québec COVID-19 JGH Site Second Data Release and Access Procedures

File Available Data

PDF icon Access Form


Contact us


Contact information for questions:

Email:coordinator-richardslab [at]

Phone: (514) 340-8222 ext. 8565 or 8380                                                 






    Back to top